News

ascopubs.org6mon
CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract ...